- Report
- March 2024
- 199 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- March 2024
- 187 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- March 2024
- 182 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- December 2023
- 105 Pages
Global
From €5747EUR$5,950USD£4,918GBP
- Report
- May 2023
- 120 Pages
Global
From €5747EUR$5,950USD£4,918GBP
- Report
- April 2024
- 372 Pages
Global
From €4781EUR$4,950USD£4,091GBP
- Report
- April 2024
- 182 Pages
Global
From €4781EUR$4,950USD£4,091GBP
- Report
- March 2024
- 175 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- February 2024
- 200 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- February 2024
- 175 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- February 2024
- 200 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- April 2024
- 135 Pages
Global
From €3766EUR$3,899USD£3,223GBP
- Report
- January 2024
- 150 Pages
Global
From €4684EUR$4,850USD£4,009GBP
- Report
- August 2023
- 150 Pages
Global
From €4105EUR$4,250USD£3,513GBP
- Report
- February 2024
- 132 Pages
Global
From €4588EUR$4,750USD£3,926GBP
- Report
- January 2024
- 200 Pages
Global
From €4008EUR$4,150USD£3,430GBP
- Report
- October 2023
- 145 Pages
Global
From €3042EUR$3,150USD£2,603GBP
- Report
- December 2023
Global
From €7244EUR$7,500USD£6,199GBP
- Report
- December 2023
- 250 Pages
Global
€4824EUR$4,995USD£4,128GBP
- Report
- October 2023
- 129 Pages
Europe
From €2028EUR$2,100USD£1,736GBP
€2897EUR$3,000USD£2,479GBP
Within the field of cardiovascular devices, Left Ventricular Assist Devices (LVADs) comprise a specialized segment aimed at supporting patients with advanced heart failure. LVADs are mechanical pumps that are implanted to assist the failing left ventricle, the main pumping chamber of the heart, by maintaining adequate blood flow throughout the body. The utility of LVADs extends from serving as a bridge to heart transplantation, to being a destination therapy for patients who are not candidates for a transplant. As technology has advanced, LVADs have become more compact and reliable, leading to improvements in patient outcomes and quality of life. The market for LVADs is influenced by several factors, including technological advancements, an aging population, and the prevalence of heart failure. Collaboration between medical device manufacturers and the healthcare community is essential in driving innovation and addressing the needs of the patient population.
Some key players in the LVAD market include Abbott Laboratories, which offers the HeartMate product line, Medtronic, known for its HeartWare HVAD system, and Berlin Heart, which provides the INCOR and EXCOR devices. Other companies active in this space are Abiomed, which has developed the Impella heart pump, and Jarvik Heart, maker of the Jarvik 2000 LVAD. Show Less Read more